All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Acute Leukemia/MDS patients with MRD receiving cord blood transplantation: higher OS and lower risk of relapse
Treatment of leukemia with transplantation of allogeneic bone marrow or stem cells from the peripheral blood is limited by the poor number of HLA-matched related donors. The purpose of this study was to conduct a retrospective analysis of outcomes in patients with Acute Lymphoid Leukemia (n=185), Acute Myeloid Leukemia (n=300) or Myelodysplastic Syndrome (n=97), who either received a transplant from a cord-blood donor (n=140), a HLA-matched unrelated donor (n=344) or from a HLA-mismatched unrelated donor (n=98).
Dr Filippo Milano and his colleagues from the Fred Hutchinson Cancer Research Centre, Seattle, USA, also analyzed if there was a difference in the relative risk of deaths and relapse between the cord-blood group and the other two unrelated donor groups with respect to numerous outcomes according to presence or absence of minimal residual disease (MRD) before transplantation. They published their data in the New England Journal of Medicine on the 8th of September 2016.
The key findings of the study are as follows:
- The percentage of patients with MRD at the time of transplantation was similar in the three groups: 33% (45/137) in the cord-blood group, 31% (104/331) in the HLA-matched group and 39% (35/90) in the HLA-mismatched group
- The survival rate was higher after receipt of a transplant from a cord-blood donor compared to receipt from a HLA-mismatched donor (HR = 1.91; 95% CI, 1.23 to 2.98; P = 0.004) although there was no difference between receipt from a cord-blood or a HLA-matched donor (HR = 1.12; 95% CI, 0.77 to 1.63; P = 0.57)
- The difference in the outcome between the cord-blood group and the HLA-matched group varied significantly according to MRD status (P = 0.04 for interaction) whereas there was only a trend toward significance in the outcome between the HLA-mismatched group and the cord-blood group according to MRD status, P = 0.08
- Among patients without MRD, the risk of death was lower in the HLA-matched group than in the cord-blood group, but the difference was not significant. In the same MRD negative patients, the risk of relapse was not significantly higher in the cord-blood group compared to the two other groups (HR = 1; HR = 1.30 for the HLA-matched group, P = 0.46 and HR = 1.28 for the HLA-mismatched group, P = 0.60). On the contrary, among patients with MRD, the risk of relapse was significantly lower in the cord-blood group compared to the two other groups (HR = 1; HR = 2.92 for the HLA-matched group, P = 0.007 and HR = 3.01 for the HLA-mismatched group, P = 0.02).
Conclusions
Even though the data analyzed here focuses on a cohort of patients based on clinical priority and non-randomization, it does provide evidence and guidance regarding difficult donor choices in circumstances where a HLA-identical sibling is not available. Future studies based on randomization would determine the differences between cord-blood and unrelated-donor transplantations.
References